Middle East and Africa Active Pharmaceutical Ingredients (API) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Middle East and Africa Active Pharmaceutical Ingredients (API) Market Segmentation, By Molecule (Small Molecule and Large Molecule), Type (Innovative Active Pharmaceutical Ingredients and Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer and Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, and Others), Type of Drug (Prescription Drugs and Over-the-Counter), Usage (Clinical and Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients and Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS and Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, and Other Therapeutic Application)- Industry Trends and Forecast to 2032

Middle East and Africa Active Pharmaceutical Ingredients (API) Market Size

• The Middle East and Africa active pharmaceutical ingredients (API) market size was valued at USD 7.78 billion in 2024 and is expected to reach USD 12.69 billion by 2032, at a CAGR of 6.30% during the forecast period
• The market growth is largely fueled by the increasing demand for both generic and innovative APIs, driven by the rising prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer across the region
• Furthermore, expanding healthcare infrastructure, strategic initiatives by local manufacturers to enhance production capabilities, and favorable regulatory environments are establishing the MEA region as a growing hub for API production. These converging factors are accelerating the uptake of advanced APIs, thereby significantly boosting the industry's growth

Middle East and Africa Active Pharmaceutical Ingredients (API) Market Analysis

• Active Pharmaceutical Ingredients (APIs), constituting the biologically active components in drugs, are increasingly critical in the pharmaceutical supply chain across the Middle East and Africa (MEA), supporting both generic and innovative drug production in response to rising healthcare needs and chronic disease prevalence
• The escalating demand for APIs in the region is primarily fueled by the growing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer, along with increasing investments in healthcare infrastructure and local pharmaceutical manufacturing capabilities
• South Africa dominated the Middle East and Africa active pharmaceutical ingredients (API) market with the largest revenue share of 28.9% in 2024, driven by a well-established pharmaceutical manufacturing sector, government initiatives to strengthen healthcare, and collaborations with global pharmaceutical companies to expand API production and innovation
• UAE is expected to be the fastest-growing country in the Middle East and Africa active pharmaceutical ingredients (API) market during the forecast period due to favorable regulatory frameworks, rising healthcare expenditure, and strategic investments in pharmaceutical R&D
• Small molecule APIs dominated the Middle East and Africa active pharmaceutical ingredients (API) market with a market share of 58.5% in 2024, driven by their established manufacturing processes, regulatory approvals, and widespread use across various therapeutic areas

Report Scope and Middle East and Africa Active Pharmaceutical Ingredients (API) Market Segmentation    

Middle East and Africa Active Pharmaceutical Ingredients (API) Market Trends

Growing Adoption of Biologic and Specialty APIs

• A significant and accelerating trend in the MEA API market is the increasing adoption of biologic and specialty APIs alongside conventional small molecules, driven by rising demand for advanced therapies in oncology, autoimmune disorders, and rare diseases

  • For instance, Biocon Biologics in South Africa produces recombinant APIs for insulin and monoclonal antibodies, catering to the growing chronic disease population and emerging treatment requirements

• The integration of novel biotechnologies and advanced manufacturing techniques enables improved efficacy, safety, and scalability of APIs, supporting the development of complex drugs tailored to regional healthcare needs
• This trend towards diversification of API portfolios is prompting manufacturers to invest in R&D and strategic collaborations with global pharmaceutical companies to enhance product offerings and market reach
• The move towards biologics and specialty APIs is fundamentally reshaping the competitive landscape of the MEA API industry, with companies such as Julphar and Pharco developing innovative biologics and high-potency APIs for chronic disease management
• The demand for advanced, targeted, and high-value APIs is growing rapidly across both established pharmaceutical hubs and emerging markets in the MEA, as healthcare providers increasingly prioritize access to novel and effective therapies

Middle East and Africa Active Pharmaceutical Ingredients (API) Market Dynamics

Driver

Increasing Healthcare Needs and Pharmaceutical Manufacturing Investments

• The rising prevalence of chronic, lifestyle-related, and infectious diseases across the MEA, combined with expanding healthcare infrastructure, is a key driver for growing demand for APIs in both domestic and regional pharmaceutical production

  • For instance, in 2024, Pharco Pharmaceuticals in Egypt expanded its API production lines to address rising demand for cardiovascular, oncology, and diabetes-related APIs in both local and export markets

• As governments and private stakeholders invest in pharmaceutical R&D, API production capacity, and local manufacturing capabilities, the region is witnessing improved production efficiency, reduced import dependency, and enhanced supply chain resilience
• Furthermore, growing awareness of affordable and high-quality treatment accessibility is making locally manufactured APIs an essential part of healthcare strategies across hospitals, pharmacies, and pharmaceutical companies
• The combination of rising regional demand, collaborations with multinational pharmaceutical companies, and the establishment of new API manufacturing facilities is driving adoption of APIs in human and veterinary pharmaceutical segments across the MEA

Restraint/Challenge

Regulatory Complexity and Quality Compliance Hurdles

• Complex, heterogeneous regulatory frameworks and strict quality standards across MEA countries pose significant challenges to API manufacturers, affecting speed to market, operational efficiency, and cost of compliance

  • For instance, inconsistent approval processes and varying pharmacopoeia requirements in Egypt, South Africa, and the UAE can delay introduction of new APIs, increase compliance costs, and create uncertainties for manufacturers operating across multiple countries

• Ensuring strict adherence to Good Manufacturing Practices (GMP), pharmacopoeia standards, and evolving national and international regulatory guidelines is crucial for maintaining API quality, efficacy, and safety
• Furthermore, high initial capital investment and sophisticated technological requirements for producing high-potency or biologic APIs can limit new entrants or smaller manufacturers from scaling operations efficiently in the region
• While some regional players invest in advanced compliance systems, quality certifications, and regulatory consulting, the fragmented regulatory landscape continues to pose barriers to uniform market penetration and rapid expansion
• Overcoming these challenges through harmonized regulations, regional capacity-building initiatives, and strict adherence to international quality standards is vital to support sustainable growth and attract both local and foreign API investments in the MEA

Middle East and Africa Active Pharmaceutical Ingredients (API) Market Scope

The market is segmented on the basis of molecule, type, manufacturer, synthesis, chemical synthesis, type of drug, usage, potency, and therapeutic application.

• By Molecule

On the basis of molecule, the Middle East and Africa active pharmaceutical ingredients (API) market is segmented into small molecules and large molecules. The small molecule segment dominated the market with the largest revenue share of 58.5% in 2024, driven by their established manufacturing processes, lower production costs, and widespread regulatory approvals. Small molecule APIs are extensively used in chronic disease treatment such as cardiovascular, diabetes, and infectious diseases, making them a backbone of the regional pharmaceutical industry. Manufacturers benefit from mature supply chains and the availability of generic formulations, which further accelerates adoption. Healthcare providers often prefer small molecules for cost-effective treatment options and broader patient accessibility. In addition, established companies in South Africa and Egypt are expanding small molecule API capacities to meet both domestic and regional demand. The demand for small molecules remains strong due to their versatility across multiple therapeutic applications.

The large molecule segment is expected to witness the fastest growth rate of 22.5% from 2025 to 2032, fueled by rising investments in biologics and advanced therapies for oncology, autoimmune disorders, and rare diseases. Large molecules, including monoclonal antibodies and recombinant proteins, offer high efficacy and targeted therapeutic action. Countries such as the UAE and Saudi Arabia are encouraging biotech API manufacturing through favorable regulations and technology transfer agreements. The increasing prevalence of complex diseases is driving pharmaceutical companies to adopt large molecule APIs for novel drug development. Integration of advanced biotechnologies and growing collaborations with global biotech firms further accelerate market adoption. The high-value nature of biologic APIs makes them attractive for both local manufacturers and multinational players in the MEA region.

• By Type

On the basis of type, the Middle East and Africa active pharmaceutical ingredients (API) market is segmented into innovative APIs and generic innovative APIs. The generic innovative API segment dominated the market with a revenue share of 55% in 2024, driven by cost-effective production, regulatory familiarity, and widespread therapeutic applicability. These APIs are particularly popular for producing affordable generic drugs for chronic diseases, making them accessible in countries with constrained healthcare budgets. Generic innovative APIs allow manufacturers to scale production quickly while maintaining compliance with local and international standards. South African and Egyptian companies are investing heavily in generic API manufacturing to capture both domestic and export markets. The segment benefits from established supply chains and partnerships with global pharmaceutical companies. In addition, generic innovative APIs contribute to regional healthcare security by reducing dependence on imported drugs.

The innovative API segment is anticipated to witness the fastest growth of 20.8% from 2025 to 2032, driven by the development of high-potency and biologic APIs targeting niche therapeutic areas. Innovative APIs include novel compounds for oncology, neurology, and rare disease treatments. Rising R&D investment, collaborations with multinational pharma companies, and technology transfer agreements are fueling growth. The UAE and Saudi Arabia are emerging hubs for innovative API manufacturing, supported by government incentives and biotech-focused initiatives. Growing adoption of precision medicine and specialty therapies is increasing demand for innovative APIs across the MEA. High-value innovative APIs also attract foreign investments, enhancing regional production capabilities.

• By Type of Manufacturer

On the basis of manufacturer, the Middle East and Africa active pharmaceutical ingredients (API) market is segmented into captive API manufacturers and merchant API manufacturers. The captive API manufacturer segment dominated the market with a revenue share of 60% in 2024, driven by pharmaceutical companies producing APIs in-house to maintain control over quality, cost, and supply chain security. Captive manufacturing allows better integration with drug formulation processes and ensures consistent availability of critical APIs. South Africa and Egypt host several large captive API facilities supporting both domestic and export needs. Companies prefer captive production for strategic therapeutic areas such as oncology, cardiovascular, and anti-diabetic drugs. The segment benefits from established infrastructure and skilled workforce availability. Captive manufacturing also mitigates risks associated with import dependency in the MEA region.

The merchant API manufacturer segment is expected to witness the fastest growth of 21% from 2025 to 2032, driven by growing outsourcing of API production and rising demand for cost-efficient supply solutions. Merchant manufacturers serve multiple pharmaceutical companies across different countries, enabling flexibility and economies of scale. The UAE and Saudi Arabia are increasingly leveraging merchant API providers to support the growing pharmaceutical industry. Outsourcing allows local and multinational companies to reduce capital expenditure while accessing high-quality APIs. Rising collaborations between regional pharma companies and global API merchants further accelerate market growth. Merchant APIs are increasingly used in both generic and innovative drug production.

• By Synthesis

On the basis of synthesis, the Middle East and Africa active pharmaceutical ingredients (API) market is segmented into synthetic APIs and biotech APIs. The synthetic API segment dominated the market with a revenue share of 65% in 2024, driven by mature, cost-efficient chemical synthesis processes and extensive application across cardiovascular, anti-diabetic, and anti-infective drugs. Synthetic APIs benefit from established manufacturing infrastructure in South Africa and Egypt. These APIs offer scalability, consistent quality, and broad therapeutic coverage, supporting high-volume production. Regional pharmaceutical companies rely heavily on synthetic APIs for generic drug formulations. The availability of raw materials and skilled chemical engineers further reinforces dominance. Strong regulatory approvals for synthetic APIs enhance their adoption in domestic and export markets.

The biotech API segment is expected to witness the fastest growth of 24% from 2025 to 2032, fueled by increasing demand for biologics, recombinant proteins, and monoclonal antibodies for chronic and rare diseases. Biotech APIs require advanced technology, specialized facilities, and skilled talent. The UAE and Saudi Arabia are promoting biotechnology hubs and collaborations with global firms. Rising prevalence of oncology and autoimmune diseases drives adoption of biotech APIs. Strategic partnerships and government support for biotech R&D are accelerating regional production. Biotech APIs are increasingly preferred for high-value, targeted therapeutic applications.

• By Chemical Synthesis

On the basis of chemical synthesis, the Middle East and Africa active pharmaceutical ingredients (API) market is segmented into acetaminophen, artemisinin, saxagliptin, sodium chloride, ibuprofen, losartan potassium, enoxaparin sodium, rufinamide, naproxen, tamoxifen, and others. The acetaminophen segment dominated the market in 2024 due to widespread usage in pain management and fever treatment across hospitals and pharmacies in the MEA. Acetaminophen APIs are widely produced by South African and Egyptian manufacturers, benefiting from mature processes and consistent quality. They form a core component in over-the-counter drugs and combination therapies. Established supply chains ensure accessibility and affordability across the region. High demand in both clinical and OTC applications supports market dominance. Manufacturers prioritize acetaminophen due to its stable market demand and regulatory familiarity.

The enoxaparin sodium segment is expected to witness the fastest growth of 23% from 2025 to 2032, driven by increasing cardiovascular disease prevalence and rising adoption of anticoagulant therapies. Enoxaparin APIs are complex, high-value products requiring specialized synthesis techniques. The UAE and Saudi Arabia are investing in local capabilities to reduce import dependency. Growing awareness of cardiovascular health and thromboembolic conditions drives demand. Collaboration with global API manufacturers ensures quality and technology transfer. Enoxaparin sodium represents a strategic high-growth niche for MEA API producers targeting hospital and specialty drug markets.

• By Type of Drug

On the basis of type of drug, the Middle East and Africa active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter (OTC) drugs. The prescription drugs segment dominated the market with a revenue share of 62% in 2024, driven by high demand for chronic disease treatment, specialty therapies, and hospital-administered medications. Prescription APIs are critical for cardiovascular, oncology, and diabetes medications, which form a significant portion of pharmaceutical consumption in South Africa, Egypt, and Morocco. Manufacturers focus on prescription APIs due to higher value, regulatory clarity, and long-term demand stability. Strategic investments in R&D and collaborations with hospitals ensure consistent supply. Strong healthcare infrastructure and insurance coverage in leading MEA countries further support prescription API adoption.

The over-the-counter drugs segment is expected to witness the fastest growth of 21% from 2025 to 2032, fueled by increasing self-medication trends and consumer preference for accessible, non-prescription treatments. OTC APIs such as acetaminophen, ibuprofen, and vitamin formulations are widely consumed across households and pharmacies. Growth is driven by rising awareness of preventive healthcare and affordability of OTC products. Egypt and South Africa are key markets for OTC API production, supported by established local manufacturers. The segment benefits from rapid urbanization and increased retail pharmacy penetration. Partnerships with global OTC API suppliers help maintain quality and expand product portfolios.

• By Usage

On the basis of usage, the Middle East and Africa active pharmaceutical ingredients (API) market is segmented into clinical and research applications. The clinical usage segment dominated the market with a revenue share of 64% in 2024, driven by high demand for APIs in hospitals, clinics, and pharmaceutical production for patient treatment. Clinical APIs support therapies for chronic and acute diseases, including cardiology, oncology, and infectious diseases. South Africa, Egypt, and Nigeria are major consumers due to well-developed healthcare infrastructure and high patient volume. Consistent regulatory approvals and local production ensure supply reliability. Manufacturers prioritize clinical APIs for their predictable demand and contribution to regional healthcare security. Government and private hospital investments also sustain robust clinical API adoption.

The research usage segment is expected to witness the fastest growth of 22% from 2025 to 2032, driven by expanding pharmaceutical R&D, clinical trials, and biotech innovation in the MEA region. Universities, research institutes, and pharma companies increasingly rely on specialty APIs for drug discovery and development. UAE and Saudi Arabia are investing heavily in research infrastructure and biotechnology hubs. Partnerships with global pharmaceutical companies facilitate technology transfer and knowledge sharing. The research segment also benefits from government initiatives supporting innovation and intellectual property frameworks. Growing demand for novel therapies accelerates adoption of research-grade APIs in emerging markets.

• By Potency

On the basis of potency, the Middle East and Africa active pharmaceutical ingredients (API) market is segmented into low-to-moderate potency APIs and potent-to-highly potent APIs. The low-to-moderate potency segment dominated the market with a revenue share of 60% in 2024, driven by widespread use in chronic disease medications, analgesics, and general therapeutic applications. These APIs are easier to manufacture, handle, and transport compared to high-potency APIs. South African and Egyptian manufacturers leverage mature production processes and regulatory approvals to supply these APIs efficiently. Low-to-moderate potency APIs form the backbone of both prescription and OTC drugs across the region. Cost-effectiveness and large patient base ensure steady demand. Regulatory familiarity further supports adoption in domestic and regional markets.

The potent-to-highly potent API segment is expected to witness the fastest growth of 24% from 2025 to 2032, driven by the increasing adoption of oncology, antiviral, and biologic therapies requiring specialized high-potency APIs. Production requires advanced containment facilities, skilled workforce, and stringent quality control. UAE and Saudi Arabia are investing in high-potency API manufacturing hubs to reduce import dependency. Collaborations with multinational pharma firms enable technology transfer and regulatory compliance. Rising prevalence of cancer and chronic viral infections increases demand for these high-value APIs. High-potency APIs represent a strategic growth segment for both local manufacturers and multinational investors targeting specialty therapies.

• By Therapeutic Application

On the basis of therapeutic application, the Middle East and Africa active pharmaceutical ingredients (API) market is segmented into cardiology, CNS & neurology, oncology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology, and other therapeutic applications. The cardiology segment dominated the market with a revenue share of 20% in 2024, driven by the high prevalence of cardiovascular diseases such as hypertension, coronary artery disease, and heart failure in South Africa, Egypt, and Nigeria. Cardiology APIs such as losartan potassium and enoxaparin sodium are in constant demand for prescription medications and hospital treatments. Regional manufacturers prioritize production due to predictable demand, regulatory approvals, and established supply chains. Strong government healthcare initiatives targeting non-communicable diseases further support growth. Collaboration with global API suppliers ensures quality and consistency.

The oncology segment is expected to witness the fastest growth of 25% from 2025 to 2032, fueled by increasing cancer incidence, adoption of biologics, and high-value specialty therapies. Oncology APIs, including monoclonal antibodies and high-potency cytotoxic compounds, require advanced manufacturing and containment. UAE and Saudi Arabia are establishing biotech and oncology API hubs to support domestic and regional demand. Rising investments in research, clinical trials, and healthcare infrastructure accelerate growth. Collaborations with multinational pharma companies enable technology transfer and regulatory compliance. The oncology segment represents a high-value opportunity for manufacturers targeting specialized therapeutic areas.

Middle East and Africa Active Pharmaceutical Ingredients (API) Market Regional Analysis

• South Africa dominated the Middle East and Africa active pharmaceutical ingredients (API) market with the largest revenue share of 28.9% in 2024, driven by a well-established pharmaceutical manufacturing sector, government initiatives to strengthen healthcare, and collaborations with global pharmaceutical companies to expand API production and innovation
• The manufacturers in the country are expanding production capacities to meet growing domestic healthcare needs as well as regional export demand, particularly for chronic disease and specialty treatments
• The widespread adoption of locally produced APIs is supported by skilled workforce availability, regulatory support, and collaborations with global pharmaceutical companies, establishing South Africa as a key hub for API production in the MEA region

The South Africa Active Pharmaceutical Ingredients (API) Market Insight

The South Africa active pharmaceutical ingredients (API) market captured the largest revenue share of 28.9% in 2024 within the MEA region, fueled by a well-established pharmaceutical manufacturing base and rising demand for both generic and innovative APIs. Healthcare providers are increasingly prioritizing locally produced APIs to ensure supply security and cost-effective treatment options. The growing focus on chronic diseases such as cardiovascular, diabetes, and oncology is further propelling the API industry. In addition, strong regulatory support, skilled workforce availability, and collaborations with multinational pharmaceutical companies are significantly contributing to market expansion. The presence of robust supply chains and advanced manufacturing facilities enhances South Africa’s position as a regional API hub.

Saudi Arabia Active Pharmaceutical Ingredients (API) Market Insight

The Saudi Arabia active pharmaceutical ingredients (API) market is projected to witness noteworthy growth during the forecast period, driven by increasing healthcare infrastructure investments and government initiatives promoting local pharmaceutical manufacturing. Rising prevalence of chronic diseases and high-value specialty treatments is fueling demand for APIs across hospitals and clinics. Saudi Arabia’s strategic focus on biotech and innovative APIs, supported by favorable regulations and incentives for R&D, is stimulating market growth. Local manufacturing and collaborations with global API suppliers enhance production capabilities and supply reliability. The region is witnessing growing adoption of both generic and innovative APIs, positioning Saudi Arabia as a leading market within the MEA.

UAE Active Pharmaceutical Ingredients (API) Market Insight

The UAE active pharmaceutical ingredients (API) market is gaining momentum due to the country’s emphasis on healthcare modernization, pharmaceutical industrialization, and diversification of the economy. Increasing investments in biotech, high-potency APIs, and innovative drug production are driving market expansion. UAE-based manufacturers are focusing on improving API production capacities to support domestic and regional demand. Collaborations with international pharmaceutical companies enable technology transfer and compliance with global quality standards. Rising awareness of chronic and lifestyle-related diseases further fuels demand for locally produced APIs. Government support for pharmaceutical infrastructure and favorable regulatory policies is expected to sustain long-term growth.

Nigeria Active Pharmaceutical Ingredients (API) Market Insight

The Nigeria active pharmaceutical ingredients (API) market is poised to grow at a significant CAGR during the forecast period, driven by rising population, expanding healthcare infrastructure, and increasing demand for affordable generic APIs. Nigerian pharmaceutical companies are scaling production of cardiovascular, anti-infective, and diabetes APIs to meet domestic demand. Growing collaborations with international API suppliers and investment in modern manufacturing facilities are enhancing quality and supply chain efficiency. The country’s focus on self-reliance in pharmaceutical production, coupled with rising awareness of chronic disease management, is driving market adoption. Increasing government support for healthcare and pharmaceutical development strengthens Nigeria’s market position within the MEA.

Middle East and Africa Active Pharmaceutical Ingredients (API) Market Share

The Middle East and Africa active pharmaceutical ingredients (API) industry is primarily led by well-established companies, including:

• CAD Middle East Pharmaceutical Industries LLC (UAE)
• Hikma Pharmaceuticals PLC (U.K.)
• Aspen Holdings (South Africa)
• Julphar (UAE)
• Amman Pharmaceutical Industries (API) (Jordan)
• Pharco (Egypt)
• Alvogen (U.S.)
• Sanofi (France)
• Aurobindo Pharma Limited (India)
• Teva Pharmaceutical Industries Ltd (Israel)
• Eva Pharma (Egypt)
• BASF (Germany)
• Vasudha Pharma (India)
• Tabuk Pharmaceuticals Manufacturing Company (Saudi Arabia)
• Quality Chemical Industries Limited (Qcil) (Uganda)
• AryoGen Pharmed (Iran)
• Bal Pharma Limited (India)

What are the Recent Developments in Middle East and Africa Active Pharmaceutical Ingredients (API) Market?

• In June 2025, EVA Pharma and CHICO Pharmaceutical announced a collaboration to localize the production of oncology APIs in the MEA region. The agreement involves a technology transfer for 10 high-potency and anti-neoplastic APIs, with production slated to take place at EVA Pharma's EU-GMP-certified facility in Egypt. This partnership aims to address the significant health and economic burden of cancer in the region by creating a more resilient and sustainable supply chain for critical cancer treatments
• In January 2025, Egypt signed a USD 120 million agreement to establish a pharmaceutical industrial hub in the Suez Canal Economic Zone. This partnership aims to enhance local pharmaceutical production and export capabilities. The facility will be managed by Arab Pharmaceutical Materials Co. (Arab API) and SCZONE Istithmar
• In December 2024, Acino, a Swiss pharmaceutical company, announced the full integration of Pharmax Pharmaceuticals, a leading UAE-based company. This move strengthens Acino's presence in the Middle East by adding a GCC and EU GMP-certified manufacturing site to its operational capabilities
• In October 2024, Health Policy Watch highlighted the urgent need for Africa to develop local manufacturing capabilities for Active Pharmaceutical Ingredients (APIs). This initiative aims to reduce reliance on imports, enhance healthcare outcomes, and stimulate economic growth across the continent
• In May 2023, MG Health, based in Lesotho, announced plans to expand its portfolio of medicinal cannabis strains and formulated extracts to meet the growing demand in key export markets. The company, compliant with EU good manufacturing practices, aims to export its products as Active Pharmaceutical Ingredients to pharmacies in the EU and other select markets

SKU-61281